[18F] fluoroestradiol radiation dosimetry in human PET studies

D. A. Mankoff, L. M. Peterson, T. J. Tewson, J. M. Link, J. R. Gralow, M. M. Graham, K. A. Krohn

Research output: Research - peer-reviewArticle

  • 59 Citations

Abstract

[18F]16α-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman. Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/ mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]). Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.

LanguageEnglish (US)
Pages679-684
Number of pages6
JournalJournal of Nuclear Medicine
Volume42
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Radiometry
Estrogen Receptors
Radiation
Nuclear Medicine
Gallbladder
Intravenous Injections
Radioactivity
Publications
Urinary Bladder
Breast Neoplasms
Weights and Measures
Liver
16-fluoroestradiol

Keywords

  • Dosimetry
  • Estrogen receptor
  • Fluoroestradiol
  • PET

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Mankoff, D. A., Peterson, L. M., Tewson, T. J., Link, J. M., Gralow, J. R., Graham, M. M., & Krohn, K. A. (2001). [18F] fluoroestradiol radiation dosimetry in human PET studies. Journal of Nuclear Medicine, 42(4), 679-684.

[18F] fluoroestradiol radiation dosimetry in human PET studies. / Mankoff, D. A.; Peterson, L. M.; Tewson, T. J.; Link, J. M.; Gralow, J. R.; Graham, M. M.; Krohn, K. A.

In: Journal of Nuclear Medicine, Vol. 42, No. 4, 2001, p. 679-684.

Research output: Research - peer-reviewArticle

Mankoff, DA, Peterson, LM, Tewson, TJ, Link, JM, Gralow, JR, Graham, MM & Krohn, KA 2001, '[18F] fluoroestradiol radiation dosimetry in human PET studies' Journal of Nuclear Medicine, vol 42, no. 4, pp. 679-684.
Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM et al. [18F] fluoroestradiol radiation dosimetry in human PET studies. Journal of Nuclear Medicine. 2001;42(4):679-684.
Mankoff, D. A. ; Peterson, L. M. ; Tewson, T. J. ; Link, J. M. ; Gralow, J. R. ; Graham, M. M. ; Krohn, K. A./ [18F] fluoroestradiol radiation dosimetry in human PET studies. In: Journal of Nuclear Medicine. 2001 ; Vol. 42, No. 4. pp. 679-684
@article{800e0171be09436396218bbbdb42599c,
title = "[18F] fluoroestradiol radiation dosimetry in human PET studies",
abstract = "[18F]16α-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman. Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/ mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]). Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.",
keywords = "Dosimetry, Estrogen receptor, Fluoroestradiol, PET",
author = "Mankoff, {D. A.} and Peterson, {L. M.} and Tewson, {T. J.} and Link, {J. M.} and Gralow, {J. R.} and Graham, {M. M.} and Krohn, {K. A.}",
year = "2001",
volume = "42",
pages = "679--684",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - [18F] fluoroestradiol radiation dosimetry in human PET studies

AU - Mankoff,D. A.

AU - Peterson,L. M.

AU - Tewson,T. J.

AU - Link,J. M.

AU - Gralow,J. R.

AU - Graham,M. M.

AU - Krohn,K. A.

PY - 2001

Y1 - 2001

N2 - [18F]16α-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman. Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/ mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]). Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.

AB - [18F]16α-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman. Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/ mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]). Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.

KW - Dosimetry

KW - Estrogen receptor

KW - Fluoroestradiol

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=0034744521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034744521&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 679

EP - 684

JO - Journal of Nuclear Medicine

T2 - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -